Cargando…

Strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis

End‐stage liver fibrosis frequently progresses to portal vein thrombosis, formation of oesophageal varices, hepatic encephalopathy, ascites, hepatocellular carcinoma and liver failure. Mesenchymal stem cells (MSCs), when transplanted in vivo, migrate into fibrogenic livers and then differentiate int...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Chenxia, Zhao, Lingfei, Duan, Jinfeng, Li, Lanjuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378173/
https://www.ncbi.nlm.nih.gov/pubmed/30635966
http://dx.doi.org/10.1111/jcmm.14115
_version_ 1783395877129289728
author Hu, Chenxia
Zhao, Lingfei
Duan, Jinfeng
Li, Lanjuan
author_facet Hu, Chenxia
Zhao, Lingfei
Duan, Jinfeng
Li, Lanjuan
author_sort Hu, Chenxia
collection PubMed
description End‐stage liver fibrosis frequently progresses to portal vein thrombosis, formation of oesophageal varices, hepatic encephalopathy, ascites, hepatocellular carcinoma and liver failure. Mesenchymal stem cells (MSCs), when transplanted in vivo, migrate into fibrogenic livers and then differentiate into hepatocyte‐like cells or fuse with hepatocytes to protect liver function. Moreover, they can produce various growth factors and cytokines with anti‐inflammatory effects to reverse the fibrotic state of the liver. In addition, only a small number of MSCs migrate to the injured tissue after cell transplantation; consequently, multiple studies have investigated effective strategies to improve the survival rate and activity of MSCs for the treatment of liver fibrosis. In this review, we intend to arrange and analyse the current evidence related to MSC transplantation in liver fibrosis, to summarize the detailed mechanisms of MSC transplantation for the reversal of liver fibrosis and to discuss new strategies for this treatment. Finally, and most importantly, we will identify the current problems with MSC‐based therapies to repair liver fibrosis that must be addressed in order to develop safer and more effective routes for MSC transplantation. In this way, it will soon be possible to significantly improve the therapeutic effects of MSC transplantation for liver regeneration, as well as enhance the quality of life and prolong the survival time of patients with liver fibrosis.
format Online
Article
Text
id pubmed-6378173
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-63781732019-03-01 Strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis Hu, Chenxia Zhao, Lingfei Duan, Jinfeng Li, Lanjuan J Cell Mol Med Reviews End‐stage liver fibrosis frequently progresses to portal vein thrombosis, formation of oesophageal varices, hepatic encephalopathy, ascites, hepatocellular carcinoma and liver failure. Mesenchymal stem cells (MSCs), when transplanted in vivo, migrate into fibrogenic livers and then differentiate into hepatocyte‐like cells or fuse with hepatocytes to protect liver function. Moreover, they can produce various growth factors and cytokines with anti‐inflammatory effects to reverse the fibrotic state of the liver. In addition, only a small number of MSCs migrate to the injured tissue after cell transplantation; consequently, multiple studies have investigated effective strategies to improve the survival rate and activity of MSCs for the treatment of liver fibrosis. In this review, we intend to arrange and analyse the current evidence related to MSC transplantation in liver fibrosis, to summarize the detailed mechanisms of MSC transplantation for the reversal of liver fibrosis and to discuss new strategies for this treatment. Finally, and most importantly, we will identify the current problems with MSC‐based therapies to repair liver fibrosis that must be addressed in order to develop safer and more effective routes for MSC transplantation. In this way, it will soon be possible to significantly improve the therapeutic effects of MSC transplantation for liver regeneration, as well as enhance the quality of life and prolong the survival time of patients with liver fibrosis. John Wiley and Sons Inc. 2019-01-11 2019-03 /pmc/articles/PMC6378173/ /pubmed/30635966 http://dx.doi.org/10.1111/jcmm.14115 Text en © 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Hu, Chenxia
Zhao, Lingfei
Duan, Jinfeng
Li, Lanjuan
Strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis
title Strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis
title_full Strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis
title_fullStr Strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis
title_full_unstemmed Strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis
title_short Strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis
title_sort strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378173/
https://www.ncbi.nlm.nih.gov/pubmed/30635966
http://dx.doi.org/10.1111/jcmm.14115
work_keys_str_mv AT huchenxia strategiestoimprovetheefficiencyofmesenchymalstemcelltransplantationforreversalofliverfibrosis
AT zhaolingfei strategiestoimprovetheefficiencyofmesenchymalstemcelltransplantationforreversalofliverfibrosis
AT duanjinfeng strategiestoimprovetheefficiencyofmesenchymalstemcelltransplantationforreversalofliverfibrosis
AT lilanjuan strategiestoimprovetheefficiencyofmesenchymalstemcelltransplantationforreversalofliverfibrosis